Risk factors for coronary heart disease: Implications of gender

Cardiovascular Research

Volumn 53, Issue 3, 2002, Pages 538-549

  Roeters Van Lennep, Jeanine E ^a   Westerveld, H Tineke ^b   Erkelens, D Willem ^b   Van Der Wall, Ernst E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coronary disease; Epidemiology; Gender

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; ESTROGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GENDER; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOKING; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DIABETES COMPLICATIONS; ESTROGENS; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFLAMMATION; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY; PSYCHOSOCIAL DEPRIVATION; RISK FACTORS; SEX; SMOKING; TRIGLYCERIDES;

EID: 0037084311     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00388-1     Document Type: Review

References (190)

1. Lifetime risk of developing coronary heart disease
2. Women's perceptions of their general health, with special reference to their risk of coronary artery disease: Results of a national telephone survey
3. Attitudes of women toward hormone therapy and prevention of heart disease
4. Sex bias in considering coronary bypass surgery
5. Differences in the use of procedures between women and men hospitalized for coronary heart disease
6. Sex differences in the management of coronary artery disease
7. Sex differences in the management and long-term outcome of acute myocardial infarction. A statewide study
8. Mortality differences between men and women following first myocardial infarction
9. Predictors of survival and the role of gender in postoperative myocardial infarction
10. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study
11. Sex, age, cardiovascular risk factors, and coronary heart disease: A prospective follow-up study of 14 786 middle-aged men and women in Finland
12. Mortality by cause for eight regions of the world: Global Burden of Disease Study
13. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987-1994
14. Epidemiology of coronary heart disease in women
15. Sex and time trends in cardiovascular disease incidence and mortality: The Framingham Heart Study, 1950-1989
16. The burden of cardiovascular diseases mortality in Europe
17. Socio-economic factors in cardiovascular disease
18. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-Year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease
19. Recent trends in acute coronary heart disease - Mortality, morbidity, medical care, and risk factors
20. Trends in serum cholesterol levels among US adults aged 20 to 74 years. Data from the National Health and Nutrition Examination Surveys, 1960-980
21. Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention
22. Coronary heart disease risk factors and menopause: A study in 1684 French women
23. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study
24. Natural menopause and cardiovascular disease risk factors. The Poland and US Collaborative Study on Cardiovascular Disease Epidemiology
25. Importance of estrogen receptors in hepatic LDL receptor regulation
26. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity
27. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: Findings from long-term follow-up of Chicago cohorts
28. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop
29. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy
30. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
31. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol And Recurrent Events (CARE) trial
32. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
34. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
35. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study
36. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
37. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women
38. Physical activity, insulin sensitivity, and the lipoprotein profile in young adults: The Beaver County Study
39. Cholesterol and other cardiovascular risk factors in a working population in Ile-de-France (France): First results of the PCV-METRA study
40. Influence of menopause on serum lipids and lipoproteins
41. Menopause and risk factors for coronary heart disease
42. Menopausal status and risk factors for cardiovascular disease
43. Guide to Preventive Cardiology for Women. AHA/ACC Scientific Statement Consensus panel statement
44. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men
45. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
46. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol
47. Plasma lipoprotein levels as predictors of cardiovascular death in women
48. Triglycerides and coronary risk in women and the elderly
49. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction
50. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
51. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women
52. Postprandial state and atherosclerosis
53. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease
54. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over 3 years
55. Obesity overrules the beneficial gender effects on triglyceride metabolism in non-obese subjects
56. Gender difference in postprandial lipemia: Importance of visceral adipose tissue accumulation
57. Menopause is associated with reduced protection from postprandial lipemia
58. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease
59. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease
60. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
61. Metabolism of high density lipoprotein subfractions
62. Lipoprotein metabolism
63. Measurement of apoproteins: Time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias
64. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
65. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
66. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec cardiovascular study
67. Apolipoprotein B and coronary artery disease in women: A cross-sectional study in women undergoing their first coronary angiography
68. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material
69. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material
70. Lipoprotein(a) and atherosclerosis
71. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study
72. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women
73. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial
74. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men
75. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study
76. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants
77. Lipoprotein(a)-cholesterol compared with sinking prebeta lipoprotein and associated relative risk of heart disease in the Framingham Heart Study
78. Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate
79. No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: Apolipoprotein A-I synthesis increased
80. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
81. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration
82. Coronary disease: Risk intervention
83. Smoking and the risk of first acute myocardial infarction
84. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes
85. Smoking cessation in relation to total mortality rates in women. A prospective cohort study
86. Impact of smoking cessation and smoking interventions in patients with coronary heart disease
87. Smoking and mortality among older men and women in three communities
88. Beneficial 6-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry
89. Smoking, lipoproteins and coronary heart disease risk. Data from the Munster Heart Study (PROCAM)
90. Prospective study of factors influencing the onset of natural menopause
91. Cross-sectional and case-controlled analyses of the association between smoking and early menopause
92. Age at natural menopause and risk of cardiovascular disease
93. Sex differences in the relationships between obesity, alcohol consumption and cigarette smoking and serum lipid and apolipoprotein concentrations in a normal population
94. A historical perspective of elevated systolic versus diastolic blood pressure from an epidemiological and clinical trial viewpoint
95. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease
96. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
97. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population
98. Systolic hypertension in the elderly. An epidemiologic assessment
99. Isolated systolic hypertension in the elderly
100. Perspectives on systolic hypertension. The Framingham study
101. Isolated systolic hypertension in the elderly: Pathophysiology and treatment
102. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials
103. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
104. British Hypertension Society guidelines for hypertension management 1999: Summary
105. Risk stratification in coronary artery disease and special populations
106. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes
107. Risk factors for coronary heart disease among older men and women: A prospective study of community-dwelling elderly
108. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study
109. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: A community-wide perspective
110. Decreased sex hormone-binding globulin predicts non-insulin-dependent diabetes mellitus in women but not in men
111. Diabetes mellitus and cardiovascular disease in women
112. Cardiovascular disease in the diabetic woman
113. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range
114. A prospective study of obesity and risk of coronary heart disease in women
115. Abdominal adiposity and coronary heart disease in women
116. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Goteborg, Sweden
117. Central adiposity and increased risk of coronary artery disease mortality in older women
118. The beneficial effects of modest weight loss on cardiovascular risk factors
119. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women
120. Parental history of cardiovascular disease and risk of stroke. A prospective follow-up of 14 371 middle-aged men and women in Finland
121. Genetic susceptibility to death from coronary heart disease in a study of twins
122. Family history as a risk factor of coronary heart disease in patients under 60 years of age
123. Predicting coronary heart disease in siblings - A multivariate assessment: The Framingham Heart Study
124. Family history of heart attack as an independent predictor of death due to cardiovascular disease
125. A prospective study of parental history of myocardial infarction and coronary heart disease in women
126. Parental history is an independent risk factor for coronary artery disease: The Framingham Study
127. Coronary risk associated with age and sex of parental heart disease in the Framingham Study
128. Homocysteine and vitamins in cardiovascular disease
129. Homocysteine, vitamin status and risk of vascular disease: Effects of gender and menopausal status
130. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study
131. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
132. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
133. Effects of sex steroids on plasma total homocysteine levels: A study in transsexual males and females
134. Effects of sub-50 oral contraceptives on homocysteine metabolism: A preliminary study
135. Plasma homocysteine and menopausal status
136. Increased plasma homocysteine after menopause
137. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years
138. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery
139. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
140. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
141. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction
142. Relationship between plasma fibrinogen and coronary heart disease in women
143. Fibrinogen and cardiovascular disorders
144. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
145. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
146. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham Study
147. Antithrombin III and procoagulant activity: Sex differences and effects of the menopause
148. Fibrinogen
149. Hormone replacement therapy and cardiovascular disease
150. Chronic infections and coronary heart disease: Is there a link?
151. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease
152. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study
153. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction
154. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: Population based study of coronary heart disease
155. Chlamydia pneumoniae infection and incident coronary heart disease: The Atherosclerosis Risk in Communities Study
156. Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile
157. Helicobacter pylori seropositivity and coronary heart disease incidence
158. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men
159. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population
160. Helicobacter pylori infection and mortality from ischaemic heart disease: Negative result from a large, prospective study
161. Helicobacter pylori and the risk of myocardial infarction
162. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
163. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
164. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
165. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
166. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
167. Psychosocial factors of coronary heart disease in women: A review
168. A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA
169. Lack of social support and incidence of coronary heart disease in middle-aged Swedish men
170. Social relations and extent and severity of coronary artery disease. The Stockholm Female Coronary Risk Study
171. Psychosocial risk factors for coronary heart disease in women
172. Social class disparities in risk factors for disease: 8-Year prevalence patterns by level of education
173. Social inequalities and atherosclerosis. The atherosclerosis risk in communities study
174. Socioeconomic status and cardiovascular risk factors in the Czech Republic
175. Low job control and risk of coronary heart disease in Whitehall II (prospective cohort) study
176. Estrogen and coronary heart disease in women
177. Age at menopause as a risk factor for cardiovascular mortality
178. Influence of age and menopause on serum lipids and lipoproteins in healthy women
179. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
180. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial
181. Effects on lipids and lipoproteins in women treated with oestradiol and progesterone
182. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
183. 17 beta-Estradiol improves postprandial lipid metabolism in postmenopausal women
184. Estrogen and the blood vessel wall
185. Hormone therapy to prevent disease and prolong life in postmenopausal women
186. Design of the Women's Health Initiative clinical trial and observational study
187. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
188. Hormone and non-hormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene